SUBSEQUENT EVENT (Details) - USD ($)						1 Months Ended	9 Months Ended
	Nov. 12, 2025	Nov. 11, 2025	Oct. 06, 2025	Oct. 01, 2025	Sep. 02, 2025	Nov. 14, 2025	Sep. 30, 2025	Dec. 31, 2020
Subsequent Event [Line Items]
Exercise price (in dollar per share)							$ 3,450	$ 3,546
Promissory Note
Subsequent Event [Line Items]
Principal amount					$ 200,000
Interest rate					0.00%
Default penalty charge amount					$ 75,000
Default penalty rate					18.00%
Purchase Agreement
Subsequent Event [Line Items]
Number of shares issued (in shares)							387,006
Proceeds from issuance							$ 4,500,000
Subsequent Event | Promissory Note
Subsequent Event [Line Items]
Principal amount			$ 270,000	$ 100,000
Interest rate			0.00%	0.00%
Default penalty charge amount			$ 101,250	$ 37,500
Default penalty rate			18.00%	18.00%
Subsequent Event | Underwriting Agreement
Subsequent Event [Line Items]
Proceeds from issuance	$ 6,300,000
Subsequent Event | Underwriting Agreement | Pre-Funded Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)		699,999
Number of shares called by warrants (in shares)		665,729
Subsequent Event | Underwriting Agreement | Series A Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)		699,999
Number of shares called by warrants (in shares)		699,999
Subsequent Event | Underwriting Agreement | Series B Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)		699,999
Option period		45 days
Number of shares called by warrants (in shares)		699,999
Subsequent Event | Underwriting Agreement | Pre-Funded Warrants, Series A Warrants And Series B Warrants
Subsequent Event [Line Items]
Public offering price (in dollars per share)		$ 1.4999
Subsequent Event | Underwriting Agreement | Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)	266,620
Exercise price (in dollar per share)	$ 2.325
Subsequent Event | Underwriting Agreement | Maximum | Pre-Funded Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)		2,152,331
Subsequent Event | Underwriting Agreement | Maximum | Series A Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)		4,666,666
Subsequent Event | Underwriting Agreement | Maximum | Series B Warrants
Subsequent Event [Line Items]
Number of shares issued (in shares)		4,666,666
Subsequent Event | Underwriting Agreement | Common Stock
Subsequent Event [Line Items]
Number of shares issued (in shares)		2,514,335
Public offering price (in dollars per share)		$ 1.50
Subsequent Event | Purchase Agreement
Subsequent Event [Line Items]
Number of shares issued (in shares)						61,862
Proceeds from issuance						$ 200,000
Subsequent Event | Securities Sales ATM Agreement
Subsequent Event [Line Items]
Number of shares issued (in shares)						45,429
Proceeds from issuance						$ 200,000
Subsequent Event | Decoy Therapeutics | Series A Preferred Stock
Subsequent Event [Line Items]
Stock issued in acquisition (in shares)	877.709
Reserved (in shares)	45.098
Subsequent Event | Decoy Therapeutics | Series B Preferred Stock
Subsequent Event [Line Items]
Stock issued in acquisition (in shares)	796.306
Subsequent Event | Decoy Therapeutics | Series A Preferred Stock And Series B Preferred Stock
Subsequent Event [Line Items]
Issued and reserved (in shares)	4,814,106